In the absence of randomized prospective trials, the EBMT registry remains an important source to survey indications, outcome and clinical risk factors in patients with solid tumours treated by auto- and allo-HCT. At the end of 2022, the EBMT registry included 65,586 HCT for solid tumours in 47,221 patients, with a slight prevalence in adults compared with children (58% vs. 42%). Auto-HCT represented 97% of the total HCT, whereas allo-HCT was used in 3% of the procedures. Multiple transplants were performed in 1/3 of the cases (Table 94.1; Figs. 94.1 and 94.2) compare activity and indications between adults and children.
Copyright 2024, The Author(s).